Immunovant, Inc. SEC filings IMVT

Immunovant, Inc. has 648 filings in SEC EDGAR's recent list, going back to Jan 23, 2019. Its latest annual report, Form ARS, was filed on Jul 22, 2026 for the period ended Mar 31, 2026. The latest quarterly report (Form 10-Q) was filed on Aug 6, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 3, 2026 (shareholder vote results). The company's fiscal year ends on March 31.

Form Description Filed Period
ARS Annual report to shareholders Jul 22, 2026 Mar 31, 2026
10-K Annual report May 20, 2026 Mar 31, 2026
ARS Annual report to shareholders Jul 9, 2025 Mar 31, 2025
10-K Annual report May 29, 2025 Mar 31, 2025
ARS Annual report to shareholders Jun 28, 2024 Mar 31, 2024
10-K Annual report May 29, 2024 Mar 31, 2024
10-K Annual report May 22, 2023 Mar 31, 2023
10-K Annual report Jun 8, 2022 Mar 31, 2022
10-K Annual report Jun 1, 2021 Mar 31, 2021
10-K Annual report Jun 29, 2020 Mar 31, 2020

Showing 10 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
IMVT (Nasdaq)
Fiscal year ends
March 31
Incorporated in
DE
Headquarters
Durham, NC
SEC filer status
Large accelerated filer
SEC CIK
1764013
Former names
Health Sciences Acquisitions Corp (until Dec 20, 2019)

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.